Key result
A drug revolving fund replacing free BP medications is linked to ~12% lower dispensing rates.
Why the study?
Expanding hypertension treatment requires ensuring access to affordable, high-quality blood pressure-lowering medications.
Does a drug revolving fund improve access and availability of blood pressure-lowering medications in primary healthcare centres in Nigeria?
Observational
Yes
Does a drug revolving fund improve access and availability of blood pressure-lowering medications in primary healthcare centres in Nigeria?
A drug revolving fund successfully expanded access to affordable blood pressure-lowering medications across 60 primary healthcare centers in Nigeria.
BACKGROUND: Expanding treatment for hypertension requires ensuring access to affordable, high-quality blood pressure (BP) lowering medications. We describe the design, implementation and evaluation of a BP-lowering medication drug revolving fund (DRF) embedded in the Hypertension Treatment in Nigeria (HTN) Programme in 60 primary healthcare centres (PHCs) in the Federal Capital Territory, Nigeria. METHODS: We used the exploration, preparation, implementation and sustainment framework to describe the DRF design and implementation and the reach, effectiveness, adoption, implementation and maintenance framework to report implementation outcomes. From June 2022 to December 2023, the DRF programme was implemented, and the data were collected from PHCs' drug stock and finance records, quarterly DRF-supportive supervision visits and the HTN Programme. We performed descriptive statistics using complete case analysis and used an interrupted time-series design to explore temporal trends in the 3-month rolling average rate of BP-lowering prescriptions dispensed. RESULTS: DRF design and implementation strategies included stakeholder engagement, leveraging the existing supply systems, developing medication and financial management protocols, training of site staff and DRF-supportive supervision visits, including joint problem solving. DRF was implemented in all 60 PHCs (100% reach). Adoption was high, with an increase in facilities selling DRF-supported medications from 80% to 100% (p value=0.01). Fidelity improved, including correct financial documentation (70%-100%; p value<0.0001) and stock cards (68%-94%; p value=0.0004). Effectiveness was high with low rates of medication stockouts of DRF-supported medications (1.7%-16%), with most medications at affordable prices, but a 12.1% drop in BP-lowering medications dispensing rate when the DRF replaced study-supplied free medication. Maintenance was high, with 100% of PHCs having a functional DRF after 1 year. CONCLUSION: A DRF programme to expand access to BP-lowering medications was implemented and effective in the Federal Capital Territory, Nigeria, and may serve as a model for other hypertension control programmes.
No takes yet. Share an insight, caveat, or question.
Shedul et al. (2025) conducted an observational in Hypertension. Drug revolving fund (DRF) for BP-lowering medications vs. Study-supplied free medication was evaluated on Implementation outcomes (reach, effectiveness, adoption, implementation, maintenance) and rate of BP-lowering prescriptions dispensed. A drug revolving fund for BP-lowering medications was implemented across 60 primary healthcare centers with 100% reach, though dispensing rates dropped 12.1% when replacing free medications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: